Literature DB >> 18978562

Adjuvant chemotherapy uptake in non-small cell lung cancer.

Tallal Younis1, Turki Al-Fayea, Kiran Virik, Wojciech Morzycki, Nathalie Saint-Jacques.   

Abstract

INTRODUCTION: Adjuvant chemotherapy in non-small cell lung cancer (NSCLC) has become a new standard of care. This study examines the uptake patterns for adjuvant chemotherapy outside of clinical trials.
METHODS: A retrospective study of all patients diagnosed with NSCLC in the year 2005 who underwent curative-intent surgery in Nova Scotia, Canada was conducted. Logistic regression models and discriminant function analyses were employed to identify cofactors associated with referral to medical oncology and/or utilization of adjuvant chemotherapy.
RESULTS: Of 540 patients with NSCLC, 108 underwent curative-intent surgery (67% lobectomy; 15% pneumonectomy; 19% wedge resection) for NSCLC (39% IA; 24% IB; 25% II; 14% III). Referral to medical oncology was observed in 44% (47 of 108) of all patients including 73% (30 of 41) of those with stage II-III. Adjuvant chemotherapy utilization was observed in 62% (29 of 47) of those referred including 73% (22 of 30) of those with stage II-III. Overall, 27% (29 of 108) of all patients received adjuvant chemotherapy, including 54% (22 of 41) of those with stage II-III. Higher uptake was significantly associated with age (younger versus older), stage (II/III versus I), and surgery type (pneumonectomy versus wedge). Weaker associations were observed with other cofactors including surgeon, health center, mean household income, and surgery-medical oncologist consult timeline.
CONCLUSIONS: The uptake of adjuvant chemotherapy in patients with resected NSCLC outside of clinical trials is low overall, but is higher among younger patients and those with more advanced stages. These uptake patterns may allow future planning of health resource utilization and/or improvement of chemotherapy utilization rates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18978562     DOI: 10.1097/JTO.0b013e318189f562

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  20 in total

1.  Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study.

Authors:  Christopher M Booth; Frances A Shepherd; Yingwei Peng; Gail E Darling; Gavin Li; Weidong Kong; William J Mackillop
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 44.544

2.  Cross-disciplinary research in cancer: an opportunity to narrow the knowledge-practice gap.

Authors:  R Urquhart; E Grunfeld; L Jackson; J Sargeant; G A Porter
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

3.  Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer.

Authors:  J A Zuccato; P M Ellis
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

4.  Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida.

Authors:  Tawee Tanvetyanon; Michelle Corman; Ji-Hyun Lee; William J Fulp; Fred Schreiber; Richard H Brown; Richard M Levine; Thomas H Cartwright; Guillermo Abesada-Terk; George P Kim; Carlos Alemany; Douglas Faig; Philip V Sharp; Merry-Jennifer Markham; Gerold Bepler; Erin Siegel; David Shibata; Mokenge Malafa; Paul B Jacobsen
Journal:  J Oncol Pract       Date:  2011-11       Impact factor: 3.840

5.  Chemotherapy uptake and wait times in early-stage non-small-cell lung cancer.

Authors:  S Gray; J Bu; N Saint-Jacques; D Rayson; T Younis
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

6.  Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study.

Authors:  Robin Urquhart; Cynthia Kendell; Gordon Buduhan; Daniel Rayson; Joan Sargeant; Paul Johnson; Eva Grunfeld; Geoffrey A Porter
Journal:  CMAJ Open       Date:  2016-01-12

7.  Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study.

Authors:  J Kankesan; F A Shepherd; Y Peng; G Darling; G Li; W Kong; W J Mackillop; C M Booth
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

8.  Uptake of oxaliplatin and bevacizumab for treatment of node-positive and metastatic colon cancer.

Authors:  Alfred I Neugut; Daniel J Becker; Beverly J Insel; Dawn L Hershman
Journal:  J Oncol Pract       Date:  2012-01-11       Impact factor: 3.840

9.  How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study.

Authors:  Robin Urquhart; Cynthia Kendell; Joan Sargeant; Gordon Buduhan; Paul Johnson; Daniel Rayson; Eva Grunfeld; Geoffrey A Porter
Journal:  Implement Sci       Date:  2012-10-25       Impact factor: 7.327

Review 10.  Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis.

Authors:  Lynne F Forrest; Jean Adams; Helen Wareham; Greg Rubin; Martin White
Journal:  PLoS Med       Date:  2013-02-05       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.